DrugPatentWatch Database Preview

Details for Patent: 7,439,241

Which drugs does patent 7,439,241 protect, and when does it expire?

Patent 7,439,241 protects MIRVASO and is included in one NDA.

This patent has sixty-four patent family members in twenty-four countries.

Summary for Patent: 7,439,241

Title:	Compounds, formulations, and methods for treating or preventing rosacea
Abstract:	In methods, compounds, and topical formulations for treatment of rosacea incorporating compounds represented by the formulas below: ##STR00001## wherein each of R.sub.1, R.sub.2, and R.sub.3 is independently hydrogen, hologen, alkyl, or alkoxy; each of R.sub.4 and R.sub.5 is independently hydrogen, alkyl, or alkoxy; and each of R.sub.6 and R.sub.7 is independently hydrogen, nitro, alkyl, or alkoxy; wherein each of A.sub.1, A.sub.3, and A.sub.4 is independently hydrogen or alkyl; and A.sub.2 is independently hydrogen or hydroxy; and wherein each of B.sub.1, B.sub.2, and B.sub.3 is independently hydrogen, hydroxy, or alkoxy; and each of B.sub.4 and B.sub.5 is independently hydrogen or alkyl, applying such compounds topically as sprays, mists, aerosols, solutions, lotions, gels, creams, ointments, pastes, unguents, emulsions, and suspensions to treat rosacea and its symptoms.
Inventor(s):	DeJovin; Jack A. (New Brunswick, NJ), DeJovin; Isabelle Jean (New Brunswick, NJ)
Assignee:	Galderma Laboratories, Inc. (Fort Worth, TX)
Application Number:	10/853,585
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 7,439,241

Glossary

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted
Galderma Labs Lp	MIRVASO	brimonidine tartrate	GEL;TOPICAL	204708-001	Aug 23, 2013		RX	Yes	Yes	➤ Sign Up	➤ Sign Up				TOPICAL TREATMENT OF FACIAL ERYTHEMA OF ROSACEA	➤ Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Patent Submitted

Non-Orange Book US Patents Family Members for Patent 7,439,241

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Patent No.	Title	Estimated Patent Expiration
8,859,551	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders	➤ Sign Up
8,557,817	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders	➤ Sign Up
8,410,102	Methods and compositions for treating or preventing erythema	➤ Sign Up
8,426,410	Compounds, formulations, and methods for treating or preventing inflammatory skin disorders	➤ Sign Up
Patent No.	Title	Estimated Patent Expiration

International Patents Family Members for US Patent 7,439,241

This preview shows a limited data set. Subscribe for full access, or try a Free Trial
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	530185	➤ Sign Up
Australia	2004242967	➤ Sign Up
Australia	2005247467	➤ Sign Up
Australia	2011231543	➤ Sign Up
Country	Document Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration

Summary for Patent: 7,439,241

For more information try a trial or see the plans and pricing